Who are Idarubicine plus Cytarabine regimen's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/idarubicine-plus-cytarabine-regimen.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Idarubicine plus Cytarabine regimen — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Idarubicine plus Cytarabine regimen (Idarubicine plus Cytarabine regimen) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination regimen (anthracycline + nucleoside analog). Area: Oncology.

phase 3 Chemotherapy combination regimen (anthracycline + nucleoside analog) Topoisomerase II (idarubicin); DNA polymerase (cytarabine) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Idarubicine plus Cytarabine regimen (Idarubicine plus Cytarabine regimen) — The First Affiliated Hospital of Soochow University. Idarubicin intercalates into DNA and inhibits topoisomerase II, while cytarabine inhibits DNA synthesis, together inducing apoptosis in leukemic cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Idarubicine plus Cytarabine regimen TARGET	Idarubicine plus Cytarabine regimen	The First Affiliated Hospital of Soochow University	phase 3	Chemotherapy combination regimen (anthracycline + nucleoside analog)	Topoisomerase II (idarubicin); DNA polymerase (cytarabine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination regimen (anthracycline + nucleoside analog) class)

The First Affiliated Hospital of Soochow University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Idarubicine plus Cytarabine regimen — Competitive Intelligence Brief. https://druglandscape.com/ci/idarubicine-plus-cytarabine-regimen. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab